drugset / Trial / NCT00198055

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

NCT00198055

Phase 2 Completed 25 enrolled Indiana University Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for reducing aggression and repetitive behavior.

Timeline

Start
2005-01
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 15 mg